Fluxome cash crisis caused by “gross mismanagement”


- Last updated on GMT

Fluxome bankruptcy threat caused by “gross mismanagement”

Related tags Finance

Management at embattled resveratrol supplier Fluxome has come in for severe criticism as the company hovers on the verge of financial collapse unless a fresh investor can be found in the coming weeks.

An observer close to a situation that saw 21 Fluxome employees at its Danish premise dismissed last Thursday without prior notice and pay for the month of September, said rash spending on new hires and premise expansion drove the company into the ground.

“While the company was struggling financially, they go and hire a new CEO, sales director [based in the US] and open offices in Maryland in the US – it’s just gross mismanagement,” ​the observer said.

“They knew they needed a new investor so it was just a bluff to get interest in the company.”

But chairman Jarne Elleholm said the company had filed for “formal reconstruction” ​in Danish courts last week almost exclusively as a result of the last-minute pull-out of an investor that would have driven the company’s ambitious omega-3 yeast extraction programme forward.

That programme was run by Dr Birgitte Wittschieben out of the now closed premise in Denmark. Its US operation continues to function.

“There was a party ready to invest but everything changed overnight when they pulled out at the last minute,” ​said Elleholm.

“Formal reconstruction”

He said the new “formal reconstruction” ​procedure in Danish law offered a better means to take the company forward than filing for bankruptcy. That motion is set to be heard in Danish courts on October 22.

He said he did not know if the 21 staff would eventually be paid – “it depends on the court”.

The “formal reconstruction” ​law gives companies more time to deal with financial problems, and de-prioritises the payment of salaries, unlike bankruptcy laws.

Board member Isabelle de Cremoux, from Paris-based investment firm, Seventure, said the firm was involved in restructuring plans.

“We were in late stage discussions with another investor with whom we, the current venture capital shareholders, were considering refinancing.”

“But he suddenly dropped out, hence the situation. If we find a new co-investor, we are likely to participate to the refinancing.”

Elleholm said 3-4 investors were in the picture for such refinancing.

Related news

Show more

Related products

show more

Elasderma: Patented advance in molecule technology

Elasderma: Patented advance in molecule technology

Nutraceuticals Group | 05-Jan-2023 | Technical / White Paper

From Atlantic Cod, Elasderma is fully water soluble, additive free and a hydrolyzed form of Elastin that contains verifiable and quantitative levels of...

Related suppliers

Follow us


View more